US reclassification could drive fresh research funding into pot sector
By Mrinalika Roy (Reuters) – The U.S. pot sector could see an influx of medical research funding from healthcare investors amid renewed interest from pharmaceutical firms, should a proposal to reclassify cannabis as a lower-risk substance be approved, industry experts said. The current classification as a Schedule I substance has limited research into cannabis due …
US reclassification could drive fresh research funding into pot sector Read More »










